C18H20N2O.C4H6O6
Neat
280.37 150.09
+5°C
Room Temperature
134002-26-9; HMW3Q5BC2M; Darifenacin intermediate IV; 3-(S)-(1-Carbamoyl-1, 1-diphenylmethyl)pyrrolidine tartrate; (S)-3-(1-Carbamoyl-1, 1-diphenylmethyl)pyrrolidine L-tartrate; 3-(S)-(-)-(1-Carbamoyl-1, 1-diphenylmethyl)pyrrolidine tartrate; 3-PYRROLIDINEACETAMIDE, .ALPHA., .ALPHA.-DIPHENYL-, (3S)-, (2R, 3R)-2, 3-DIHYDROXYBUTANEDIOATE (1:1); 3-PYRROLIDINEACETAMIDE, .ALPHA., .ALPHA.-DIPHENYL-, (S)-, (R-(R*, R*))-2, 3-DIHYDROXYBUTANEDIOATE (1:1); 3-Pyrrolidineacetamide, alpha, alpha-diphenyl-, (3S)-, (2R, 3R)-2, 3-dihydroxybutanedioate (1:1); 3-Pyrrolidineacetamide, alpha, alpha-diphenyl-, (S)-, (R-(R*, R*))-2, 3-dihydroxybutanedioate (1:1); RefChem:585192; (S)-2, 2-Diphenyl-2-(pyrrolidin-3-yl)acetamide (2R, 3R)-2, 3-dihydroxysuccinate; 3-(S)-(+)-(1-Carbamoyl-1, 1-diphenylmethyl)pyrroloidine-L-(+)-tartarate; MFCD09750973; (S)-Alpha, Alpha-Diphenyl-3-pyrrolidine acetamide L-Tartaric acid salt; 3-(S)-(+)-(1-Carbamoyl-1, 1-diphenylmethyl)pyrroloidine-L-(+)-tartrate; (2R, 3R)-2, 3-dihydroxybutanedioic acid;2, 2-diphenyl-2-[(3S)-pyrrolidin-3-yl]acetamide; (S)-2, 2-Diphenyl-2-(pyrrolidin-3-yl)acetamide(2R, 3R)-2, 3-dihydroxysuccinate; (S)-a and a-Diphenyl-3-pyrrolidineacetamide L-Tartrate; HRXFENQYWZZQMX-NUFNRNBZSA-N
(2R, 3R)-2, 3-dihydroxybutanedioic acid;2 and 2-diphenyl-2-[(3S)-pyrrolidin-3-yl]acetamide
InChI=1S/C18H20N2O.C4H6O6/c19-17(21)18(16-11-12-20-13-16,14-7-3-1-4-8-14)15-9-5-2-6-10-15;5-1(3(7)8)2(6)4(9)10/h1-10,16,20H,11-13H2,(H2,19,21);1-2,5-6H,(H,7,8)(H,9,10)/t16-;1-,2-/m11/s1